AmBisome
Mylan pharmaceuticals, India
$1058.00-
SelectSpecification/Number
-
ParameterDetailed information
-
NoticeCustoms clearance instructions
-
Required readingConsumption notice
- Description
- Information
INDICATIONS AND USAGE（适应症）
AmBisome is indicated for the following:
•Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
•Treatment of Cryptococcal Meningitis in HIV-infected patients.
•Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
•Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites.
DOSAGE（服用剂量）
AmBisome is not interchangeable or substitutable on a mg per mg basis with other amphotericin B products. Different amphotericin B products are not equivalent in terms of pharmacodynamics, pharmacokinetics and dosing.
AmBisome should be administered by intravenous infusion, using a controlled infusion device, over a period of approximately 120 minutes.
An in-line membrane filter may be used for the intravenous infusion of AmBisome, provided THE MEAN PORE DIAMETER OF THE FILTER IS NOT LESS THAN 1.0 MICRON.
NOTE: An existing intravenous line must be flushed with 5% Dextrose Injection prior to infusion of AmBisome. If this is not feasible, AmBisome must be administered through a separate line.
Infusion time may be reduced to approximately 60 minutes in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased.
The recommended initial dose of AmBisome for each indication for adult and pediatric patients is as follows:
Empirical therapy: 3 mg/kg/day
Systemic fungal infections(Aspergillus, Candida, Cryptococcus): 3 - 5 mg/kg/day
Cryptococcal meningitis in HIV-infected patients: 6 mg/kg/day
Dosing and rate of infusion should be individualized to the needs of the specific patient to ensure maximum efficacy while minimizing systemic toxicities or adverse events.
Doses recommended for visceral leishmaniasis are presented below:
Immunocompetent patients: 3 mg/kg/day (days 1 - 5) and 3 mg/kg/day on days 14, 21
Immunocompromised patients: 4 mg/kg/day (days 1 - 5) and 4 mg/kg/day on days 10, 17, 24, 31, 38
For immunocompetent patients who do not achieve parasitic clearance with the recommended dose, a repeat course of therapy may be useful.
For immunocompromised patients who do not clear parasites or who experience relapses, expert advice regarding further treatment is recommended.
ADVERSE REACTIONS（不良反应）
Abdominal pain
Asthenia
Back pain
Blood product transfusion reaction
Chills
Infection
Pain
Sepsis
Chest pain
Hypertension
Hypotension
Tachycardia
Diarrhea
Gastrointestinal hemorrhage
Nausea
Vomiting
Alkaline phosphatase increased
ALT (SGPT) increased
AST (SGOT) increased
Bilirubinemia
BUN increased
Creatinine increased
Edema
Hyperglycemia
Hypernatremia
Hypervolemia
Hypocalcemia
Hypokalemia
Hypomagnesemia
Peripheral edema
Anxiety
Confusion
Headache
Insomnia
Cough increased
Dyspnea
Epistaxis
Hypoxia
Lung disorder
Pleural effusion
Rhinitis
Pruritus
Rash
Sweating
Hematuria
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/f7be6506-4d20-401e-a0ff-02ad7c33158a/spl-doc?hl=AmBisome
AmBisomeinformation
No information yet!!!